Entering text into the input field will update the search result below

Repligen updates guidance after Q4 results

  • Repligen (NASDAQ:RGEN +3.8%) Q4 results: Revenues: $16.4M (+6.5%); COGS: $8.1M (+50.0%); R&D Expense: $1.3M (-7.1%); SG&A: $5M (+47.1%); Operating Income: $0.06M (-98.8%); Net Loss: ($0.4M) (-112.1%); Loss Per Share: ($0.01) (-110.0%).
  • FY2014 results: Revenues: $63.5M (-6.9%); COGS: $28M (+11.1%); R&D Expense: $5.6M (-23.3%); SG&A: $17.2M (+35.4%); Operating Income: $10.7M (-53.3%); Net Income: $8.2M (-49.1%); EPS: $0.25 (-50.0%); Quick Assets: $62M (-16.0%).
  • 2015 Guidance: Revenues: $72M - 75M; product gross margin: 55 - 57%; operating expenses: $60M - 62M; SG&A expense: $21M - 23M; R&D expense: $5M - 6M; income from operations: $12M - 14M; net income: $8M - 10M; taxes: ~4M.

Recommended For You

More Trending News

About RGEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RGEN--
Repligen Corporation